



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: HTLV-I Peptide GAG-1a (102-117) PPSSPTHDPDSDPQI

Catalog Number: 1463

Lot Number: 150220

Provided: 0.5 mg, lyophilized.

Description: Residues 102-117 from HTLV-I p19 Gag.

Sequence: PPSSPTHDPDSDPQI

Purity: 95.62%

Special Characteristics: Gag-1a represents the immunodominant C-terminal of HTLV-I p19^{gag}. This peptide is recognized by 92% of all HTLV-I and 9% of all HTLV-II sera tested.
Dilutions should be made in 10 mM carbonate buffer, pH 9.6 (Sigma, Catalog #C3041).
[Protocol: ELISA for Detection of HTLV-I and HTLV-II Positive Sera](#)

Molecular Formula: C72H107N19O28

Molecular Weight: 1686.77

Recommended Storage: Keep at -20°C lyophilized and -80°C after reconstitution.

Contributor: Dr. Renu B. Lal.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Lal RB, Rudolph DL, Griffis KP, Kitamura K, Honda M, Coligan JE, Folks TM. Characterization of immunodominant epitopes of *gag* and *pol* gene-encoded proteins of human T-cell lymphotropic virus type I. *J Virol* **65**:1870-1876, 1991.

Lal RB, Brodine SK, Coligan JE, Roberts CR. Differential antibody responsiveness to p19 *Gag* results in serological discrimination between human T lymphotropic virus type I and type II. *J Med Virol* **35**:232-236, 1991.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HTLV-I Peptide GAG-1 α (102-117) PPSSPTHDPDSDPQI from Dr. Renu Lal." Also include the references cited above in any publications.

A US Government Patent (#5738805) has been issued on this research material. Scientists at for-profit institutions or who intend commercial use of this reagent must contact Ms. Lisa Blake-DiSpigna at email address LBlake-DiSpigna@cdc.gov and specify in the email the name of the reagent, and a description of the intended use of the reagent.

Last Updated:

August 01, 2019

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.